Industry City has announced today that Sight Diagnostics, a medical device company that provides accurate blood diagnostics from just two drops of blood in minutes, has joined the campus’ growing cohort of biotech companies.
Sight Diagnostics, whose global footprint includes locations in Tel Aviv and London, has selected the Brooklyn campus as its first North American location, and will utilize its new 6,237 s/f space for office functions and operational distribution.
“We couldn’t be more thrilled to establish our first U.S. headquarters in Industry City. Its unrivaled facilities and easy access to New York City and New Jersey will be pivotal as we expand our team from 20 by the end of this year to more than 35 employees in 2021,” said Sight Diagnostics’ U.S. General Manager, Ron Melts.
“Industry City also offers ample space and quick access to JFK Airport to support the global distribution of our FDA 510(k)-cleared blood analyzer.”
Sight Diagnostics brings a team of 20 people to IC, with plans to expand and hire across all positions. Sight Diagnostics joins several companies in the medical device industry on campus including Prime Discoveries, which provides laboratories with rapid COVID-19 panels, and Suneris, a biotech firm developing a plant-based gel that enables blood clotting for veterinary uses.
“Scaling startups like Sight Diagnostics have a unique challenge when it comes to selecting a space because they need to efficiently serve all sides of the business. In this new flagship location, Sight will seamlessly co-locate a beautiful, client-facing front-of-house area, a safe and clean workspace, and storage and shipping operations for their product, all under one roof,” said Kathe Kramer Chase, Director of Leasing at Industry City.
“Sight Diagnostics is completely revolutionizing blood diagnostics with its technology; inventiveness and pioneering are integral to the entrepreneurial spirit of our campus, and we are sure Sight will feel right at home at Industry City. We are thrilled to be part of Sight’s next chapter as it enters the North American market and continues its ground-breaking work.”
Sight Diagnostics has created an FDA 510(k)-cleared blood analyzer to measure complete blood count (CBC), the most commonly ordered blood test in the world. Using machine vision and AI, Sight has automated the measuring of more than 19 blood parameters to deliver fast and accurate CBC results from just two drops of blood. The new technology allows Sight’s OLO analyzer to be much more compact and versatile than legacy systems, which tend to be bulky, expensive to operate, and labor-intensive. By providing lab-grade results on blood tests quickly, Sight OLO enables more timely treatment for patients in need.
Sight Diagnostics was represented by Oron Tanami of Brooklyn Connect Realty in the transaction. Industry City was represented by Matthew Stewart, Leasing Associate and Jeff Fein, Senior Vice President of Leasing at Industry City.
As part of hte strategic redevelopment of Industry City Belvedere Capital and Jamestown have invested over $450 million into the property and leased more than three million square feet of space.